Young Blood Plasma Parkinson's Disease Study One-Month Results to Be Introduced at the Texas Neurological Society Winter Conference in Austin on February 1st
AUSTIN, Texas, Jan. 31, 2019 /PRNewswire/ -- The Neurology Center, a medical group practice of top doctors devoted to excellence in care, located in Houston, Texas, working in conjunction with two leading neurology and anti-aging specialists from Houston, will introduce on Friday initial, one-month results of their randomized controlled study of intravenously administering NuPlasma® young blood plasma into the first fourteen of twenty Parkinson's disease patients.
In a landmark investigation that addresses a well-known neurological disorder that affects more than 10 million people worldwide, for which there has been previously no known treatment that can slow the progression of the disease, the randomized double-blind, placebo-controlled study, designed to evaluate the efficacy of 25 ml/kg intravenous NuPlasma® young Fresh Frozen Plasma (yFFP) administered in two doses over three days, realized dramatic improvements in critical disease-conditions such as pain, facial expression, speech, handwriting, tremors, rigidity and falling. yFFP recipients achieved improvements in 30/43 assessment categories, with yFFP outperforming the placebo in every assessment subset.
Full and continuing study disease assessment and blood laboratory data is accessible online at: www.youngplasmastudy.com.
About NuPlasma - NuPlasma is a Blood Bank operating under FDA, AABB and CLIA's Good Manufacturing Practice regulations. Located in San Marcos, Texas, NuPlasma is the world's first blood bank to collect young plasma exclusively from volunteer 18 – 25 year old donors. NuPlasma is dedicated to Making Lives Better® by providing physicians with exceptional quality, selection and service.
*The use of Blood and Blood Products such as Plasma in the United States is restricted only to the issuance of a prescription by a licensed physician.